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In 2008, an estimated 6,300 Iowans will die from cancer, 14 times the number caused by auto 
fatalities. Cancer is second only to heart disease as a cause of death.  
These projections are based upon mortality data the State Health Registry of Iowa receives from  
the Iowa Department of Public Health. The Registry has been recording the occurrence of cancer  
in Iowa since 1973, and is one of 15 population-based registries and three supplementary registries 
nationwide providing data to the National Cancer Institute. 
With 2008 Cancer in Iowa the Registry makes a general report to the public on the status of cancer. 
This report will focus on:
 • a description of the Registry and its goals;
 • cancer estimates for 2008;
 • a special section on non-Hodgkin lymphoma;
 • brief summaries of recent/ongoing research projects;
 • a selected list of publications from 2007.
The State Health Registry of Iowa is the 
best statewide resource for determining 
the burden of cancer on the Iowa 
population and assessing trends in the 
occurrence of cancer over time.  
THE STATE HEALTH REGISTRY OF IOWA
 
Cancer is a reportable disease as stated in the Iowa Administrative 
Code. Cancer data are collected by the State Health Registry of 
Iowa, located at The University of Iowa in the College of Public 
Health’s Department of Epidemiology. The staff includes more 
than 50 people. Half of them, situated throughout the state, 
regularly visit hospitals, clinics, and medical laboratories in Iowa 
and neighboring states to collect cancer data. A follow-up program 
tracks more than 99 percent of the cancer survivors diagnosed 
since 1973. This program provides regular updates for follow-
up and survival. The Registry maintains the confidentiality of the 
patients, physicians, and hospitals providing data.
In 2008 data will be collected on an estimated 16,000 new cancers 
among Iowa residents. Noninvasive cases of bladder cancer are 
included in the estimates for bladder cancer, to be in agreement 
with the definition of reportable cases of the Surveillance, 
Epidemiology, and End Results (SEER) Program of the National 
Cancer Institute.
Since 1973 the Iowa Registry has been funded primarily by the 
SEER Program of the National Cancer Institute. Iowa represents 
rural and Midwestern populations and provides data included in 
many National Cancer Institute publications. Beginning in 1990  
a small percent of the Registry’s annual operating budget has  
been provided by the state of Iowa. Beginning in 2003, the 
University of Iowa has also been providing cost-sharing funds.  
The Registry also receives funding through grants and contracts 
with university, state, and national researchers investigating  
cancer-related topics.
The Goals of the 
Registry are to:
•  assemble and report 
measurements of  
cancer incidence,  
survival and mortality 
among Iowans;
• provide information  
on changes over time 
in the extent of disease  
at diagnosis, therapy, 
 and patient survival;
• promote and conduct 
studies designed to 
identify factors relating 
to cancer etiology, 
prevention and control; 
• respond to requests 
from individuals and 
organizations in the  
state of Iowa for cancer 
data and analyses; 
• provide data and  
expertise for cancer 
research activities  
and educational 
opportunities. 
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CANCER PROjECTIONS FOR 2008
Estimated Number of New Cancers in Iowa for 2008
Estimated Number of Cancer Deaths in Iowa for 2008
 
5TOP 10 TYPES OF CANCER IN IOWA ESTIMATED FOR 2008
Cancer Deaths in Females
Type                # of Cancers % of Total
Lung 730 24.4
Breast 430 14.3
Colon & Rectum 330 11.0
Pancreas 180 6.0
Ovary 180 6.0
Non-Hodgkin Lymphoma 130 4.3
Leukemia 120 4.0
Uterus 100 3.3
Brain 80 2.7
Kidney & Renal Pelvis 70     2.3
All Others 650 21.7
Total 3000
Cancer Deaths in Males
Type                # of Cancers % of Total
Lung 1000 30.3
Prostate 350 10.6
Colon & Rectum 310 9.4
Pancreas 180 5.5
Leukemia 160 4.8
Non-Hodgkin Lymphoma 140 4.3
Esophagus 140 4.3
Bladder 100 3.0
Kidney & Renal Pelvis 100 3.0
Brain 100 3.0
All Others 720 21.8
Total 3300
New Cancers in Females
Type # of Cancers % of Total
Breast 2120 27.5
Lung 980 12.7
Colon & Rectum 940 12.2
Uterus 470 6.1
Non-Hodgkin Lymphoma 340 4.4
Skin Melanoma 280 3.7
Ovary 240 3.1
Thyroid 220 2.9
Leukemia 210 2.7
Kidney & Renal Pelvis 200 2.6
All Others 1700 22.1
Total 7700
New Cancers in Males
Type                 # of Cancers % of Total
Prostate 2100 25.3
Lung 1250 15.0
Colon & Rectum 930 11.2
Bladder  620 7.5 
(invasive and noninvasive)  
Non-Hodgkin Lymphoma 400 4.8
Skin Melanoma 340 4.1
Kidney & Renal Pelvis 330 4.0
Leukemia 290 3.5
Oral Cavity 220 2.7
Pancreas 180 2.2
All Others 1640 19.7
Total 8300
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced through 
positive health practices such as smoking cessation, physical exercise, healthful dietary habits, and alcohol 
consumption in moderation. Early detection through obtaining recommended screening tests and regular 
health checkups can improve cancer survival.  
6Non-Hodgkin lymphoma (NHL) is the 6th most 
common cancer that the State Health Registry of 
Iowa will track this year. This cancer typically arises 
in lymphoid tissue in the lymphatic system, which is 
part of the body’s immune system. In the lymphatic 
system, a network of lymph vessels carries clear 
fluid called lymph. Lymph vessels lead to small, 
round organs called lymph nodes. Lymph nodes are 
filled with lymphocytes, a type of white blood cell. 
The lymph nodes identify and react to bacteria or 
other harmful substances that may be in the lymph. 
Groups of lymph nodes are found in the neck, 
underarms, chest, abdomen, and groin. Other parts 
of the lymphatic system include the tonsils, spleen, 
and thymus. These parts of the lymphatic system 
give rise to nodal NHL. There is also lymphoid 
tissue in the oral cavity, pharynx, stomach, small 
intestine, lung, skin, and brain in which lymphomas 
can arise; these are called extranodal NHL.
NHL has been one of the most rapidly increasing 
types of cancer in the United States, having more 
than doubled in incidence (new NHL diagnoses) since 
the 1970s. While a small fraction of this increase 
is due to AIDS-related NHL, for the most part the 
reason is unknown. Figure 1 shows incidence rates 
of NHL by gender for the state of Iowa for 1973-
2005. Male incidence has always been greater than 
female incidence. In both genders, the increase  
in incidence was most rapid during the 1980s.  
When compared to the 8 other SEER geographic 
areas, Iowa’s rates have generally been in the 
middle over this 33-year period. Mortality rates 
(shown in figure 1) have also increased over this 
timeframe, and are also higher in males than 
females. In the 1990s in Iowa, the annual rate 
of increase in NHL incidence lessened, and an 
increase in the survival rates was observed,  
which has led to more recent declines in the 
mortality rate (number of deaths due to NHL).        
NHLs are characterized by the abnormal growth 
of lymphocytes. Lymphocytes exist either as 
B-cells or T-cells. B-cells develop into plasma cells 
that produce antibodies to fight infections. T-cells 
directly attack foreign invaders, such as bacteria or 
viruses. NHLs are often divided into 
subtypes based on how the cancer 
cells look under a microscope, 
their pattern of growth, and other 
specialized tests done on the 
cancer cells. It is important to 
accurately determine the subtype 
of NHL because subtypes can 
behave differently and often require 
different treatments.  
Subtype classification schemes  
for NHL have been modified several 
times over the past few decades 
based on increasing knowledge  
of this disease. Between 1992  
and 2005, there were 8,800 NHLs 
diagnosed among Iowans, and 
NON-HODGKIN LYMPHOMA
Figure 1.  Age-adjusted incidence and mortality rates 
for non-Hodgkin lymphoma by sex, Iowa, 1973-2005  
(Rates are expressed per 100,000 population  
and age-adjusted to 2000 U.S. population)
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7these were about evenly split between men and 
women. 71% were nodal NHLs and 29% were 
extranodal. Of the 8,800 NHLs, 87% were B-cell 
lymphomas, 7% T-cell lymphomas, and the 
remainder were of other or unknown subtype. 
Among the B-cell lymphomas, the two major 
subtypes were diffuse large B-cell lymphoma (46%) 
and follicular lymphoma (24%). Follicular lymphoma 
is typically low grade and slow growing, while 
diffuse large B-cell lymphoma is more aggressive. 
Recent advances in our understanding of the 
molecules and genes that cause lymphoma cells  
Figure 2a. Age-adjusted incidence for common subtypes of  
non-Hodgkin B-cell lymphoma by sex, Iowa, 1992-2005  
Figure 2b. Age-specific incidence rates for common subtypes of  
non-Hodgkin B-cell lymphoma by sex, Iowa, 1992-2005 
to behave abnormally are allowing us to classify 
lymphomas based not only on their appearance 
under the microscope, but also on the gene 
expression patterns of the lymphoma cells.  
Such genetic approaches will likely continue to  
lead to different classification schemes in the years 
ahead. Most importantly, it is hoped this will allow  
for more individualized approaches to therapy. 
The exact causes of NHL are not known. Research 
shows that certain risk factors increase a person’s 
chance of developing this disease. Having a 
weak immune system (from an inherited  
 condition, human immunodeficiency  
 virus (HIV) infection, or certain drugs),  
 increases the risk for NHL. Certain  
 types of infections, including HIV,  
 Epstein-Barr virus (EBV), Helicobacter  
 pylori (bacteria that can cause  
 stomach ulcers), Human T-cell   
 leukemia/lymphoma virus (HTLV-1),  
 and Hepatitis C, increase the risk  
 of some subtypes of lymphoma.  
 Various environmental risk factors,  
 such as polychlorinated biphenyls  
 (PCBs), pesticides, solvents, and hair  
 dyes have also been associated 
 with increased risk of NHL. As a result,  
 occupations such as farming are  
 associated with increased risk.  
 The risk of developing this disease  
 increases with age. Most people with  
 NHL are older than 60.   
 Researchers have also noted  
 differences in the incidence patterns  
 of NHL subtypes. As an example, in  
 Figure 2a age-adjusted incidence  
 rates for 1992-2005 are shown for  
 diffuse large B-cell lymphoma   
 (DLBCL) and for follicular lymphoma  
 by sex and in Figure 2b age-specific  
 incidence rates are shown. DLBCL  
 male incidence rates are consistently 
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8higher than female incidence rates by year of  
diagnosis and by age at diagnosis. Both sexes 
show a dramatic increase in age-specific rates  
after age 50 that peaks at age 75-79 for females 
but at 80-84 for males. However, follicular  
lymphoma shows much greater similarity between 
males and females, and the increase with age is 
not as pronounced. To researchers, these findings 
suggest that while these subtypes both arise from 
the same cell of origin (B-cell), they may evolve  
as unique diseases that have unique risk factors.    
A population-based case-control study, in which 
four SEER registries (including Iowa) participated, 
has been contributing important findings in this 
regard. A listing of some of the findings, published 
in 2007, is provided in the publications section 
of this monograph. Briefly, for DLBCL, late birth 
order and high body mass index appear to 
increase risk as well as genetic factors that lead 
to immune dysfunction. On the other hand, several 
other risk factors appear to increase the risk of 
follicular lymphoma such as greater height, use of 
permanent hair dyes before 1980 (when certain 
carcinogenic dyes were used), and genetic factors 
related to DNA repair and to direct DNA damage 
from environmental carcinogens.    
There are no recommended screening tests for  
the early detection of NHL. This leaves reducing 
incidence and/or improving therapy as the two 
major options to reduce NHL mortality. Traditionally, 
treatment for NHL has consisted of chemotherapy 
and radiation therapy. More recently, immuno-
therapy has been added to treatment regimens.  
As shown in Figure 3, five-year relative survival 
percents have increased over the past 30 years in 
Iowa from 42.5% for NHL diagnosed during 1973  
to 1975 to 67.2% for NHL diagnosed during 2000  
to 2003. The biggest increases in these survival 
percents occurred initially between 1976-79 and 
1980-83 and more recently between 1996-99  
and 2000-03. Reasons for the former likely relate  
to the discovery and wider use of new chemotherapy 
regimens and diagnostic tests, while the reason for 
the latter relates to the development and use of 
Figure 3. 5-year relative survival percents by time period, Iowa, 1973-2003  
(Source:  SEER*Stat, version 6.3.6)
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9immunotherapy, most notably Rituximab. Rituximab 
was approved in 1997 by the Food and Drug 
Administration. It is a monoclonal antibody  
that attaches to a specific protein on the surface  
of most B-cells. This drug has had an enormous  
impact on the treatment of NHL involving B-cell 
subtypes, which account for the majority of 
lymphomas. This impact is likely reflected in  
Figure 4, where five-year survival percents are 
increasing for the two common subtypes of B-cell 
NHL as this drug becomes more widely used as 
common therapy. Researchers are still developing 
new approaches that take optimal advantage of 
Rituximab. In addition, ongoing studies are exploring 
whether the next generation of monoclonal antibody 
treatments are superior to Rituximab, or whether 
other novel approaches to lymphoma therapy  
might result in additional improvements. These  
novel approaches include individualized lymphoma 
vaccines or drugs that interfere with abnormal 
activities in lymphoma cells. 
Figure 4.  5-year relative survival percents for common subtypes of  
non-Hodgkin lymphoma, Iowa, 1992-2003  
(Source:  SEER*Stat, version 6.3.6)
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A point and click cancer 
data retrieval system  
is now available for Iowa  
at www.public-health.uiowa.
edu/shri. Click on Iowa  
Cancer Data. Try it out!
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The State Health Registry of Iowa is participating in 
around two dozen funded studies during 2008. Brief 
descriptions of a few of these studies are provided.
The Agricultural Health Study
The Agricultural Health Study is a long-term study 
of agricultural exposures (including pesticides) 
and chronic disease (especially cancer) among 
commercial or private pesticide applicators 
(and their spouses, if married) in Iowa and North 
Carolina. The study is funded primarily by the 
National Cancer Institute. We are in the 16th year  
of the study. 
In the first five years, 89,658 subjects (58,564 in 
Iowa and 31,094 in North Carolina) were enrolled  
in the study. This total for Iowa included 31,877  
private applicators (farmers), 21,771 spouses of  
private applicators, and 4,916 commercial  
applicators. Enrollment consisted of completing 
questionnaires about past exposures and health. 
The second phase of the study for private applica-
tors and their spouses was completed at the end  
of 2003. It involved a telephone interview, a mailed 
dietary questionnaire, and collection of a cheek  
cell sample from all consenting cohort members.  
The telephone interview asked about pesticide use 
since enrollment, current farming and work  
practices, and health changes. The dietary health 
questionnaire asked about cooking practices and 
types of foods eaten. The cheek cells will be used 
to understand possible links between genetics, 
exposures, and disease. For commercial applica-
tors, the second phase of the study was completed 
at the end of 2005. The study’s third phase began 
in 2005, involves updating information about expo-
sures and health, and is ongoing.  
Since 1997, cohort members have been linked  
annually to mortality and cancer registry incidence 
databases in both states. In addition, mortality data 
on the cohort are being obtained from the National 
Death Index. More information about recent results 
from this study, the study background, frequently 
asked questions, other resources (internet & tele-
phone) for agricultural health information, references 
for publications to date, and information for scientific 
collaborators can be found at the website,  
www.aghealth.org. The abstract and/or full text 
are available for the publications at the website.  
The cancer-related references for recent publications 
are provided in the last section of this report.      
Studies involving Non-Hodgkin  
Lymphoma (NHL)
The State Health Registry of Iowa (SHRI), along with 
researchers at the Mayo Clinic participated in a 
collaborative, population-based case-control study 
of NHL involving researchers at the National Cancer 
Institute and three other Surveillance, Epidemiology, 
and End Results (SEER) registries. The main 
objective of the study was to better characterize 
risk factors for NHL. In Iowa, 364 live patients newly 
diagnosed with NHL between july 1, 1998 and june 
30, 2000 were enrolled. A similar number of 
population controls participated. Blood samples 
were sought from study participants. The SHRI also 
coordinated the acquisition of pathology reports, 
slides and tissue blocks from all SEER centers.  
The slides were reviewed to determine the reliability 
of NHL pathologic classification. More recently,  
we are collaborating with researchers at the Mayo 
Clinic to investigate whether genes with functional, 
common variant polymorphisms involved in immune 
function and regulation are associated with overall 
survival from NHL among these patients. To achieve 
this aim, medical record reviews were performed to 
obtain more detailed information on the treatment 
received for NHL. In addition, NHL patients not 
diagnosed and/or treated at the University of Iowa 
Hospitals and Clinics or at the Mayo Clinic are being 
contacted by Registry staff to see if they have a 
family history of hematopoietic cancer. If yes, they 
are being invited to participate by providing a family 
RESEARCH PROjECTS DURING 2008 
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history and by providing blood samples from 
themselves and their relatives. These research 
activities resulted in several publications during 
2007. The references for these are provided in  
the last section of this report. 
Geographical Information Systems 
The State Health Registry of Iowa is involved with 
research utilizing a geographical information system 
to develop and test a methodology for identifying 
regions of excess cancer burden for breast and 
colorectal cancer in Iowa. It will refine measures of 
geographic access to cancer prevention, treatment 
and screening services in Iowa by computing values 
using fine-scaled geographic data on individuals, the 
spatial choices of individuals and the locations of 
service providers. A regional simulation workbench 
will generate the expected range and variations in 
the cancer burden measures for small geographic 
areas of Iowa based on local demographic 
characteristics of the area and statewide cancer 
burden rates. Results can be used to plan more 
appropriate cancer prevention and control programs.
A Centers for Disease Control and Prevention 
supported project using Registry data has led 
to a book “Geocoding Health Data: The Use of 
Geographic Codes in Cancer Prevention and 
Control, Research and Practice” recently published 
by CRC Press. Edited by seven faculty at the 
University of Iowa (Rushton, Armstrong, Gittler, 
Greene, Pavlik, West and Zimmerman), this book 
presents a state-of-the-art discussion on the  
current technical and administrative developments 
in geographic information science. In particular,  
it discusses how geocoded residential addresses 
can be used to examine the spatial patterns of 
cancer incidence, staging, survival, and mortality. 
Many of its examples and illustrations use State 
Health Registry of Iowa data.
The Registry has also provided data for maps 
created for use by the Iowa Consortium for 
Comprehensive Cancer Control. The maps were 
created by Dr. Gerard Rushton, Professor of 
Geography at the University of Iowa, and graduate 
students Kristen Beyer, Zunqiu Chen, and Veronica 
Escamilla. These maps can be used for planning 
purposes for cancer prevention and control 
activities. These maps can be viewed at www.uiowa.
edu/~gishlth/ICCCCMaps/index.htm. The Registry 
has received support from the National Cancer 
Institute to develop a web-based mapping program 
that will permit cancer maps to be prepared by 
Cancer Registries. This project is being pursued  
with the Utah and the New jersey Cancer Registries.
Pooled Analyses 
Today, researchers are increasingly looking to 
combine their study data with that of other studies 
evaluating similar outcomes. The State Health 
Registry of Iowa has been involved with such pooling 
activities for studies involving residential radon  
and lung cancer, diet and cancer, second cancers, 
and non-Hodgkin lymphoma. During 2007 these 
activities have resulted in several publications,  
which are listed in the last section of this report.  
SEER Patterns of Care Studies 
SEER Patterns of Care Studies are conducted to 
satisfy a U.S. Congressional directive to the National 
Cancer Institute to “assess the incorporation of  
state-of-the-art cancer treatment into clinical practice 
and the extent to which cancer patients receive 
such treatments and include the results in such 
assessment in the biennial reports.” This year’s 
Patterns of Care Study will involve thyroid, 
glioblastoma, and adolescent/young adult cancers 
(acute lymphoblastic leukemia, germ cell, lymphoma, 
sarcoma) diagnosed between january 1, 2006 and 
December 31, 2006. The objectives of the SEER 
Patterns of Care Study are to: 1) describe the use  
of adjuvant therapy, which has been verified with 
the treating physician, in a community setting, 
2) characterize the practice patterns in different 
communities, 3) describe more completely the use 
of surgery in the treatment of specific cancers, 
4) compare the patterns of treatment for cancer  
over time, 5) compare patterns of care by age and 
race, 6) describe effect of co-morbid conditions on 
treatment, and 7) describe treatment by hospital 
characteristics: i.e. for profit vs. not for profit, 
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teaching vs. non-teaching, disproportionate share 
status, etc. The SHRI has been involved with these 
types of studies over the past 20 years.  
Adolescent and Young Adult Component
Compared to younger and older aged cancer 
populations, SEER data suggest that the adolescent 
and young adult (AYA) population between the ages 
of 15 and 39 years has seen little or no improvement 
in cancer survival rates for decades. In 2005 the 
National Cancer Institute partnered with the Lance 
Armstrong Foundation and developed a Progress 
Review Group (PRG) to address the special research 
and cancer care needs of the AYA cancer population. 
The PRG suggested a special emphasis should 
be placed on collection of current and complete 
treatment data for a sample of the AYA cancer 
population. This feasibility study is SEER’s first attempt 
to address the needs of the AYA cancer population 
through a modification to its Patterns of Care Study 
design, focusing on contacting AYAs for permission 
to obtain all outpatient and inpatient medical records 
relating to the cancers of interest and for them to 
complete a brief survey. The State Health Registry  
of Iowa will be enrolling 50 patients in the AYA portion 
of the study, diagnosed between july 2007 and 
August 2008.
The Iowa Women’s Health Study
This is a population-based cohort of 41,837 Iowa 
women, aged 55-69 in 1986, who were recruited 
to determine whether diet, body fat distribution and 
other risk factors were related to cancer incidence. 
Exposure and lifestyle information was collected in  
a baseline mailed survey and subsequently in several 
follow-up mailed surveys. Mortality and cancer 
incidence have been ascertained annually since  
1986 through linkage to the State Health Registry  
of Iowa databases and the National Death Index.   
The project has been extremely productive with over 
200 publications, some of which occurred in 2007 
and are listed in the references provided in the last 
section of this report. This past year SHRI personnel 
obtained pathologic materials for several hundred 
women in this study who have been diagnosed with 
colorectal cancer as part of a collaborative study 
with researchers at the Mayo Clinic. The primary 
aims of the study are to examine associations between 
environmental factors and colorectal cancer subtypes 
exhibiting DNA patterns defined by a microsatellite 
instability phenotype, Ki-ras mutation status, p53 
mutation status, and gene-specific methylation patterns. 
The study will be ongoing for the next few years.
Elderly Cancer Survivors: Cognitive Outcomes  
and Markers of Neurodegeneration
The goal of this study is to examine the long-term 
outcomes following treatment for breast cancer.   
Funded by a University of Iowa Institutional Grant 
from the UI Cancer and Aging Program, this study 
is interested in learning whether breast cancer 
treatments may affect how the brain ages in later 
years. The project seeks to invite women over the 
age of 65 who have undergone successful treatment 
of breast cancer at least ten years earlier with no 
evidence of recurrence or other cancer diagnosis 
since then. The results from this research study  
may help us understand whether there is a 
contribution of different cancer treatments to brain 
changes and eventually learn how these changes  
may be prevented. 
Cooperative Agreements and Other Registries
The SHRI maintains cooperative agreements with 
several hospital cancer registries and other agencies/
entities. Some of the latter include:
 * Iowa Department of Public Health
 * Iowa Consortium for Comprehensive  
  Cancer Control
 * The University of Iowa
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